Published • loading... • Updated
Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist
Summary by The Manila Times
2 Articles
2 Articles
The Manila TimesReposted by 
Carroll County Mirror-Democrat
Carroll County Mirror-DemocratAntag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist
AT7687 demonstrated a favorable safety and tolerability profile with no adverse GI tolerability signals identifiedOnce-weekly dosing potential and demonstrated target engagement across the doses tested were confirmedPreclinical data from non-human primates showed additional weight loss and significant improvements in insulin sensitivity and body composition with AT7687 in combination with cagrilintideThese data further reinforce the potential of…
·Manila, Philippines (the)
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right1Center0Last UpdatedBias Distribution100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium
